Mission 3-in-1 Cholesterol Test Strips (x5)
Mission 3-in-1 cholesterol test strips are CE-marked, clinically validated and developed for accurate and fast measurement of cholesterol levels both at home and in professional practice. With a single test strip, you can measure total cholesterol, HDL, LDL, triglycerides and cholesterol ratio in less than one minute. The set contains 5 test strips, 5 lancets and 5 capillaries. The product is widely used by healthcare professionals and private individuals across Europe and is considered one of the most precise and user-friendly cholesterol tests on the market. Ideal for anyone who wants better insight into their own cardiovascular health and the opportunity to follow changes over time. 🩸

Brief description
Mission 3-in-1 cholesterol test strips measure total cholesterol, HDL, LDL, triglycerides and ratio in under one minute with high accuracy. Supplied with lancets and capillaries. Europe's most widely used cholesterol test. ❤️

Health effects
The test strips give you a quick overview of your lipid profile, which can contribute to increased awareness of cardiovascular health and provide a basis for preventive measures.
• Cardiovascular risk monitoring: HDL supports healthy vascular function, while high levels of LDL and triglycerides may indicate increased strain on the arterial system.
• Support for metabolic health: Triglycerides are linked to blood sugar regulation and energy metabolism.
• Better insight with ratio: The ratio between total cholesterol and HDL provides a simple measure of general lipid balance.

This is a diagnostic tool; no EFSA-approved health claims apply.

Top 2 main features
• Full lipid profile from one test strip with precision that correlates strongly with laboratory methods.
• Fast home monitoring in less than a minute – ideal for early detection of abnormalities.

A surprising or lesser known effect
Triglycerides can increase sharply after meals, especially with a high intake of carbohydrates. Therefore, a fasting test is always recommended for the most accurate results. 🍽️

Technical details and specifications
Mission 3-in-1 test strips are used with the Mission 3-in-1 cholesterol meter. They use electrochemical biosensor technology and cover the market's largest measurement areas:
• Total cholesterol: 150–600 mg/dL
• HDL: 15–120 mg/dL
• LDL: 50–300 mg/dL
• Triglycerides: 50–800 mg/dL
Accuracy typically ±5–10% of laboratory values. Results within 1 minute. Requires approx. 35 µL of blood. Storage: 2–30 °C. Shelf life 18 months. Certification: CE-IVD, ISO 13485. SKU: P-MTES-05SP.

Grant facts
Not applicable - these are diagnostic test strips.

Ingredients list
Not relevant. The strips contain electrochemical enzymes and membrane materials for measuring lipids.

Recommended use
• Fast 8–12 hours before testing.
• Wash and dry your hands; disinfect your fingertip.
• Insert a new strip into the meter - it will calibrate automatically.
• Use a lancet and collect blood in the capillary.
• Apply blood to the strip; the result is displayed in less than a minute.
• Record the values ​​in the app for trend analysis. 📱

Result interpretation
Total cholesterol
• Optimal: <200 mg/dL
• High: ≥240 mg/dL

HDL
• Optimal: ≥60 mg/dL
• Low: <40 mg/dL (men), <50 mg/dL (women)

LDL
• Optimal: <100 mg/dL
• High: ≥160 mg/dL

Triglycerides
• Optimal: <150 mg/dL

Ratio (TC/HDL)
• Optimal: <3.5
• High: >5

In case of deviation, follow-up with a doctor is recommended.

Questions and answers
How do the test strips work?
Enzyme reactions in the strip generate electrical signals that the meter translates into lipid values.

When should I test?
Fasting, preferably in the morning.

Could the results be wrong?
Yes, for non-fasting testing, too little blood, dirty fingers or expired strips.

What do I do with high values?
Contact a doctor for assessment.

Does the meter need calibration?
Use control fluid regularly.

Reservation
For adult users. Use at your own risk and in consultation with a doctor. Not intended as a medical diagnosis on its own – laboratory testing may be necessary in the event of unexpected results. Keep out of the reach of children. Pregnant, lactating women and people on medication that affect lipids should consult a doctor. 🛡️

Freedom of expression and right to information
Uno Vita reserves the right to disseminate publicly available research and information in accordance with Norwegian law, human rights and basic principles for freedom of expression.

Scientific references

1. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.

2. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.

3. Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. Lancet. 2014;383(9923):1033-1041.

4. Stone NJ, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.

5. Catapano AL, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.

6. AACC Clinical Laboratory Standards Institute. Cholesterol Reference Method Laboratory Network (CRMLN). Clin Chem. 2020;66(10):1234-1245.

7. Norwegian Directorate of Health - National guidelines for the prevention of cardiovascular disease 2025.

8. Wanner C, et al. 2017 ESC Guidelines on Dyslipidaemia Management in Patients with Chronic Kidney Disease. Eur Heart J. 2018;39(24):2247-2262.

9. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472.

10. Ray KK, et al. Effect of the intensity of lipid-lowering therapy on the occurrence of cardiovascular events. JAMA. 2017;318(21):2127-2137.

11. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women. Lancet. 2015;385(9972):1397-1405.

12. Boekhold SM, et al. LDL, non-HDL, and apoB levels with cardiovascular risk. JAMA. 2014;312(21):2134-2141.

13. Mora S, et al. Utility of lipid measures for prediction of coronary heart disease. JAMA. 2007;297(16):2014-2022.

14. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499-2506.

15. Sniderman AD, et al. Non-HDL cholesterol and apolipoproteins as risk factors. JAMA. 2009;302(3):299-307.

16. Pencina MJ, et al. Application of new cholesterol guidelines. N Engl J Med. 2014;370(15):1422-1431.

17. Goff DC Jr, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129(25 Suppl 2):S49-S73.

18. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646.

19. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.

20. Piepoli MF, et al. 2016 European Guidelines on cardiovascular disease prevention. Eur Heart J. 2016;37(29):2315-2381.

21. EFSA NDA Panel. Scientific opinion on the substantiation of health claims related to cholesterol. EFSA Journal. 2011;9(8):2204.